Nature: a magical small molecule -- s63845 is expected to treat many kinds of cancers

Recently, a research report published in the international journal Nature from Walter and Eliza hall in Australia According to the research of the Institute, a special compound can effectively block the action of a key protein, which is crucial for maintaining the sustainable development of at least one quarter of cancers Relevant research may help researchers develop new methods to effectively kill cancer cells, and develop treatments such as acute myeloid leukemia, lymphoma and the like A variety of solid tumors (melanoma, etc.) and other new cancer therapies S63845, a small molecule discovered by Servier company, is able to target the BCL2 family protein MCL1, which is essential for the sustainable growth of cancer cells Lessone, a researcher, pointed out that inhibiting MCL1 protein can effectively target multiple types of cancer MCL1 protein is very important for many cancers, because it is a survival promoting protein, which can make cancer cells escape the process of programmed cell death A large number of studies on cancer models have shown that compound s63845 can effectively target cancer cells that depend on MCL1 protein survival In the past, radiotherapy and chemotherapy are effective methods to fight against cancer cells, which can reduce the death rate of cancer patients But these techniques often "implicate" healthy cells, causing side effects such as extreme physical weakness S63845 can not only cut off the life support system of cancer, but also be tolerated by normal cells in a certain dose, showing a good development prospect The researchers believe that s63845 can not only effectively resist various types of cancer, but also be tolerated by normal cells in a certain dose Olivier geneste, Ph.D., said that preclinical research revealed the potential drug formation of MCL1, which is a very valuable and challenging target for the research team In the near future, they will launch clinical research on the development of MCL1 inhibitors.